Charles River Laboratories Endosafe Trillium

Status™ COVID-19/Flu A&B, rapid antigen immunoassay

Status COVID 19 Flu AB rapid antigen immunoassay

Principle: For the direct detection of SARS-CoV-2, Influenza Type A and Type B

Automation: NO

Approvals: FDA EUA

Suitability: Rapid Detection

Capital equipment required: NO


A rapid immunoassay for the simultaneous direct detection and differential diagnosis of SARS-CoV-2, Influenza Type A and Type B antigen from nasopharyngeal swab specimens. Flocked nasopharyngeal swab for superior specimen collection and patient comfort.

Key Points:

Sensitivity and Specificity

  • SARS-CoV-2 - Sensitivity 93.9%, Specificity 100%
  • Flu A - Sensitivity 91.4%, Specificity 95.7%
  • Flu B - Sensitivity 87.6%, Specificity 95.9%

Features and benefits:

  • Fast results:
    Visual read-out in 15 minutes, and no equipment needed!
    Approved under FDA Emergency Use Authorization (EUA)
  • Swab included:
    Kit includes extraction buffer vials and flocked nasopharyngeal swabs for superior specimen collection and patient comfort.

Click here for more information


Company contact details:

Hardy Diagnostics view full details
Santa Maria
United States

Website: Visit Website
Tel: +[1] 805-346-2766

safe and easy sterility testing patented dual needle unique sterisart septum watch video

Data Integrity as an Indicator of Quality Control Issues

BioMerieux at PDA 2023

Condalab Brochure Download

Charles River Webinar Recombinant Cascade Reagent

Get our eNewsletter
Over 7,000 microbiology professionals get our weekly eNewsletter - subscribe now and find out why!